British pharmaceutical giant GSK has not met required ethical and regulatory standards in the marketing and prescription ...

A complaint against GSK accusing it of a major breach of the pharma industry's code of practice on prescribing information ...

GSK has been found guilty of bringing discredit on the pharma industry after a complainan | GSK has been found guilty of ...

GSK’s $1.9 billion takeover of Sierra Oncology has delivered the first new product, with the EU approval of Omjjara for the treatment of enlarged spleen (splenomegaly) or symptoms in adult ...

GSK's submission for the approval of Omjjara was supported by data from the pivotal MOMENTUM study and a subpopulation of adult patients with anaemia from the SIMPLIFY-1 phase III trial. MOMENTUM was ...

UK pharm major GSK (LSE: GSK) has breached the ABPI Code of Practice for the Industry and brought discredit upon, and ...

(Reuters) -British pharmaceutical giant GSK has not met required ethical and regulatory standards in its marketing and ...

and over 30% will discontinue treatment due to anaemia [1-3] Omjjara addresses the key manifestations of myelofibrosis, specifically anaemia, constitutional symptoms, and splenomegaly Earlier ...

London: British pharmaceutical major GlaxoSmithKline (GSK) has failed to meet the required regulatory and ethical standards ...